Last $37.96 USD
Change Today +0.52 / 1.39%
Volume 64.7K
FLDM On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 11:58 AM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

fluidigm corp (FLDM) Snapshot

Open
$37.49
Previous Close
$37.44
Day High
$38.18
Day Low
$36.93
52 Week High
02/27/14 - $49.46
52 Week Low
10/13/14 - $21.71
Market Cap
1.1B
Average Volume 10 Days
302.9K
EPS TTM
$-1.29
Shares Outstanding
28.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FLUIDIGM CORP (FLDM)

Related News

No related news articles were found.

fluidigm corp (FLDM) Related Businessweek News

No Related Businessweek News Found

fluidigm corp (FLDM) Details

Fluidigm Corporation develops, manufactures, and sells microfluidic systems worldwide. It offers BioMark HD System that performs high-throughput and single-cell targeted gene expression analysis, single nucleotide polymorphism (SNP) genotyping, and digital polymerase chain reaction (PCR) using Fluidigm DELTAgene and SNPtype assays, other chemistries, and Fluidigm Dynamic Array and Digital Array integrated fluidic circuits (IFCs). The company also provides C1 Single-Cell Auto Prep System, which enables the isolation, processing, and profiling of individual cells for genomic analysis for applications comprising single-cell targeted gene expression, single-cell micro ribonucleic acid (RNA) analysis, single-cell messenger RNA analysis, and single-cell targeted DNA sequencing using the company’s C1 Single-Cell Auto Prep Array IFCs and C1 reagent kit. In addition, it offers EP1 System, which performs SNP genotyping using Fluidigm SNPtype assays or TagMan assays, as well as end-point digital PCR using TaqMan assays, and Fluidigm Dynamic Array and Digital Array IFCs; and Access Array System to enable PCR-based target enrichment, barcoding, and the tagging of targeted resequencing libraries. Further, the company provides Dynamic Array, Digital Array, C1 Single-Cell Auto Prep Array, and Access Array IFCs; DELTAgene and SNPtype assays; and Access Array Target-Specific primers. It serves academic institutions; clinical laboratories; and pharmaceutical, biotechnology, and agricultural biotechnology companies in single-cell genomics, applied genotyping, and sample preparation for targeted re sequencing markets. Fluidigm Corporation distributes its products through support organizations, distributors, or sales agents, as well as through its direct sales force. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.

325 Employees
Last Reported Date: 03/12/14
Founded in 1999

fluidigm corp (FLDM) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $425.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $311.6K
Executive Vice President of Legal Affairs, Ge...
Total Annual Compensation: $312.0K
Executive Vice President of Research & Develo...
Total Annual Compensation: $308.1K
Executive Vice President of Worldwide Manufac...
Total Annual Compensation: $293.4K
Compensation as of Fiscal Year 2013.

fluidigm corp (FLDM) Key Developments

Fluidigm Corporation Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2014 and Full Year of 2015

Fluidigm Corporation provided preliminary unaudited revenue guidance for the fourth quarter and full year of 2014 and full year of 2015. The company announced total revenue for the fourth quarter of 2014 is expected to be approximately $33.4 million. Organic revenue for the fourth quarter of 2014 (excluding revenue attributable to the DVS Sciences acquisition, comprised of the CyTOF® 2 system and proteomics analytical consumables) is expected to be approximately $25.2 million. Total revenue for the full year of 2014 is expected to be approximately $116.4 million. Organic revenue for the full year of 2014 (excluding revenue attributable to the DVS Sciences acquisition, comprised of the CyTOF® 2 system and proteomics analytical consumables) is expected to be approximately $95.9 million. Fluidigm projects total revenue for the full year of 2015 to be between $142 million and $149 million. 2015 revenue projections incorporate an estimated negative currency related impact of 3% to 4% at the midpoint of the range.

Fluidigm Corporation Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 08:30 AM

Fluidigm Corporation Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 08:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Gajus V. Worthington, Co-Founder, Chief Executive Officer, President and Director.

Fluidigm Corporation Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 11:00 AM

Fluidigm Corporation Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 11:00 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Ana Petrovic, Director of Investor Relations and Strategy, Vikram Jog, Chief Financial Officer and Principal Accounting Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FLDM:US $37.96 USD +0.52

FLDM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Affymetrix Inc $11.14 USD -0.06
Luminex Corp $18.20 USD -0.08
NanoString Technologies Inc $12.77 USD +0.24
Pacific Biosciences of California Inc $7.90 USD +0.02
Sequenom Inc $3.70 USD +0.0752
View Industry Companies
 

Industry Analysis

FLDM

Industry Average

Valuation FLDM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.1x
Price/Book 6.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FLUIDIGM CORP, please visit www.fluidigm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.